Can I Take NAC (N-Acetylcysteine) with Leqvio (Inclisiran)?

What Is Inclisiran (Leqvio) and Who Typically Takes It?

Inclisiran is a small-interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 inside hepatocytes, reducing the production of PCSK9 protein and thereby increasing LDL-receptor recycling on the liver cell surface. The result is a sustained LDL-C reduction of approximately 50 percent from a twice-yearly subcutaneous injection, based on the ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020.

FDA approval was granted in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy.

Who Are the Women Most Likely to Be Prescribed Inclisiran?

Three groups of women appear most often in real-world prescribing:

• Postmenopausal women with ASCVD. Estrogen withdrawal accelerates atherogenic dyslipidemia. LDL-C rises an average of 10 to 14 mg/dL in the two years surrounding the final menstrual period, and statin intolerance is more common in women than men.
• Women with heterozygous familial hypercholesterolemia. HeFH affects approximately 1 in 250 people regardless of sex, but cardiovascular events occur roughly 10 years earlier in women with untreated HeFH compared with the general female population.
• Women with statin-associated muscle symptoms (SAMS). Women experience SAMS at higher rates than men, making a non-statin LDL-lowering option like inclisiran clinically relevant.

Sex-Specific Pharmacokinetics

Inclisiran is delivered as a subcutaneous injection; it distributes rapidly to the liver via GalNAc ligand targeting and is metabolized by nucleases. The ORION-11 trial pharmacokinetic substudy did not report sex-stratified PK differences requiring dose adjustment, and the FDA label does not specify a sex-based dose change. Body weight and renal function affect exposure more than sex does. Women with low body weight (<60 kg) may show marginally higher peak plasma concentrations, though this has not translated to a dose adjustment in clinical guidelines.

What Is NAC and Why Do Women Take It?

N-acetylcysteine is the acetylated form of the amino acid L-cysteine. It replenishes intracellular glutathione, the body's primary antioxidant. Clinically, NAC has two well-established uses: as an IV antidote for acetaminophen overdose and as an oral mucolytic for chronic obstructive pulmonary disease. In women's health specifically, it appears in three distinct contexts.

NAC for PCOS

Oral NAC at doses of 1,200 to 1,800 mg per day has been compared with metformin in women with PCOS and found to improve insulin sensitivity, reduce androgen levels, and support ovulation in small randomized trials. A 2021 systematic review in Fertility and Sterility found that NAC improved ovulation rates compared with placebo in anovulatory PCOS, though trial quality was rated low to moderate. Women with PCOS also carry a significantly elevated cardiovascular risk profile, which is the condition that inclisiran targets.

NAC as an Antioxidant Supplement

Outside clinical indications, many women take NAC as a general antioxidant, at doses ranging from 600 mg to 1,800 mg daily. Interest has grown in its potential role in reducing oxidative stress in metabolic syndrome, which overlaps heavily with both PCOS and postmenopausal cardiovascular disease.

NAC for Respiratory and Mucolytic Purposes

Some women with chronic bronchitis, cystic fibrosis, or COVID-19 sequelae take NAC for mucolytic purposes at doses of 600 mg twice daily, a standard mucolytic dose supported by European Respiratory Society guidance.

Does NAC Interact with Inclisiran? The Pharmacology Explained

No interaction between NAC and inclisiran appears in the FDA prescribing label for Leqvio, in peer-reviewed pharmacokinetic studies, or in current interaction databases. To understand why, it helps to look at what each compound actually does.

Pharmacokinetic Interaction Risk: Very Low

Inclisiran is not metabolized by cytochrome P450 enzymes. It is broken down by tissue nucleases after hepatic uptake. NAC is deacetylated to cysteine and then incorporated into glutathione or excreted. The two compounds share no metabolic pathway. Neither inhibits nor induces the other's clearance. There is no shared transporter system identified in current literature that would create a clinically meaningful pharmacokinetic interaction.

Pharmacodynamic Interaction Risk: Theoretical, Not Established

A pharmacodynamic interaction, where two agents have overlapping or opposing biological effects, deserves more thought here. Both inclisiran and NAC have been associated with cardiovascular benefit, but through entirely different mechanisms:

• Inclisiran lowers LDL-C by increasing hepatic LDL-receptor density.
• NAC may reduce oxidative modification of LDL and lower lipoprotein(a) in some studies, though this is not a consistent finding across trials.

A 2018 study in Lipids in Health and Disease found that high-dose NAC (1,800 mg/day for 12 weeks) reduced Lp(a) by approximately 20 percent in a small sample of adults with elevated Lp(a). Inclisiran has a modest Lp(a)-lowering effect as well, reported at approximately 18 percent reduction in ORION-10. If a woman is taking both with the goal of reducing Lp(a), the effects could add together, but this has not been studied in a controlled trial and should not be assumed to be simply additive.

There is no antagonistic pharmacodynamic interaction identified. NAC does not raise LDL-C, does not block PCSK9 inhibition, and does not interfere with RNA interference biology.

The WomanRx Interaction Classification for NAC + Inclisiran:

| Interaction type | Risk level | Clinical action needed | |---|---|---| | Pharmacokinetic (absorption, metabolism, excretion) | None identified | None | | Pharmacodynamic (opposing effects) | None identified | None | | Pharmacodynamic (additive LDL or Lp(a) lowering) | Theoretical, minor | Inform prescriber; monitor lipid panel | | Pregnancy co-exposure risk | Inclisiran contraindicated in pregnancy; NAC used clinically in pregnancy for specific indications only | Do not combine without specialist oversight | | PCOS-specific metabolic interaction | No adverse interaction; may have complementary metabolic effects | Inform prescriber; reassess lipid goals on therapy |

Inclisiran in Women with PCOS: A Gap in the Evidence

Women with PCOS carry a lipid profile that is distinct from standard dyslipidemia. They tend to have elevated triglycerides, low HDL-C, and small dense LDL particles, with LDL-C that may not look alarming on a standard panel but represents a higher atherogenic burden than the number suggests. The Endocrine Society's 2023 PCOS guideline recommends cardiovascular risk assessment and lipid management in all women with PCOS, particularly those with obesity or metabolic syndrome.

Inclisiran has not been studied in a PCOS-specific trial. The ORION program enrolled women with HeFH or established ASCVD, populations that skew older and postmenopausal. Whether the LDL-lowering magnitude, safety, and durability of inclisiran translate to younger women with PCOS-driven dyslipidemia is an open question. This is a genuine evidence gap, and women with PCOS should know that the decision to use inclisiran is being extrapolated from trials in a different demographic.

NAC, by contrast, has been studied specifically in PCOS populations for metabolic endpoints. The combination of NAC (as a PCOS metabolic adjunct) and inclisiran (as a lipid-lowering agent) in the same woman is theoretically reasonable given the absence of any identified interaction, but no trial has evaluated this combination in women with PCOS.

How Inclisiran Works Across Life Stages in Women

Reproductive Years (18 to 40)

Inclisiran in women of reproductive age is uncommon because cardiovascular risk is generally lower and because the drug is contraindicated in pregnancy (see the Pregnancy section below). Women with HeFH who are in their reproductive years may be candidates, and contraception counseling is mandatory in that setting. Statins, the standard first-line agents, are also contraindicated in pregnancy, so the reproductive-age conversation often involves careful sequencing of therapy around pregnancy planning.

Perimenopause (Typically 45 to 55)

Perimenopause is when cardiovascular risk begins to accelerate in women. Fluctuating estrogen levels destabilize lipid metabolism, and LDL-C can rise unpredictably even in women with previously normal panels. A 2021 analysis in the Journal of the American Heart Association found that women in early perimenopause showed a greater increase in atherogenic lipoproteins than age-matched men, suggesting that aggressive lipid management during this window may have long-term cardiovascular benefit. Inclisiran is not specifically labeled for perimenopausal lipid changes, but women in this stage with HeFH or prior cardiovascular events are eligible.

Postmenopause

Postmenopause is the life stage where most women in real-world practice receive inclisiran. Cardiovascular disease becomes the leading cause of death in women after menopause. Statin intolerance is common in postmenopausal women, partly because estrogen has a protective effect on muscle that diminishes after menopause, increasing vulnerability to statin myopathy. Inclisiran's injectable, twice-yearly dosing removes the daily adherence burden and sidesteps the muscle-related side effects of statins.

Pregnancy, Lactation, and Contraception: Required Reading

Inclisiran is contraindicated in pregnancy. This is the single most important safety fact for any woman of reproductive age who is prescribed Leqvio.

Pregnancy

Animal studies showed fetal harm at doses lower than the human therapeutic dose. The FDA label for inclisiran states that it should not be used during pregnancy and that women of reproductive potential should use effective contraception during treatment. Because inclisiran is dosed every six months after the initial two doses, a woman who becomes pregnant between injections should inform her prescriber immediately. No human pregnancy outcome data exist for inclisiran. Cholesterol is required for fetal development, and PCSK9-silencing during gestation carries theoretical fetal risk from lipid depletion, though this has not been studied in humans.

Novartis excludes women who are pregnant or planning pregnancy from clinical trials, so the human teratogenicity data are entirely absent. The ACOG guidance on lipid management in pregnancy recommends stopping all non-essential lipid-lowering therapy, and inclisiran would fall under that category without exception.

Lactation

No data exist on the transfer of inclisiran into human breast milk, its effect on milk production, or its effect on a breastfed infant. Given the lack of data and the drug's mechanism affecting a fundamental metabolic pathway, the FDA label advises against use during breastfeeding. If inclisiran is medically necessary for a postpartum woman, breastfeeding should be discontinued.

Contraception Requirements

Any woman of childbearing potential who is prescribed inclisiran should use reliable contraception throughout treatment. Because the drug is active for months after each injection, conception should be avoided during the entire treatment period. Women who want to try to conceive should discuss the timing of their last injection with their prescriber well in advance, ideally at least six months before attempting pregnancy, though no specific washout period has been formally validated in humans given the absence of human reproductive safety data.

NAC in Pregnancy

NAC has a different profile. It is used in pregnancy in clinical settings, most notably as the antidote for acetaminophen overdose (IV acetylcysteine), which has a well-established safety record even in the first trimester. Oral NAC has been studied in small trials for preterm labor prevention and as an adjunct in recurrent pregnancy loss, with no consistent evidence of fetal harm at typical doses. The FDA does not assign pregnancy categories under the current labeling system, but NAC's clinical use in pregnancy for specific indications is supported by decades of toxicology data. Routine supplementation of NAC in pregnancy purely for antioxidant purposes is not standard of care and should be discussed with an OB-GYN or maternal-fetal medicine specialist.

Who This Combination Is Right For (and Who Should Be Cautious)

May Be Appropriate

• A postmenopausal woman with established ASCVD taking inclisiran for LDL management who also takes NAC 600 mg daily for antioxidant purposes. No interaction is identified; she should tell her cardiologist or internist.
• A woman with PCOS and dyslipidemia taking NAC as a metabolic adjunct who is subsequently prescribed inclisiran for cardiovascular risk reduction. No interaction exists, and the metabolic goals may be complementary. Lipid panel monitoring is standard regardless.
• A woman with statin intolerance who is on inclisiran and wants to explore NAC for its antioxidant properties. Reasonable in the absence of any identified interaction; dose NAC at standard supplemental amounts (600 to 1,800 mg daily).

Use With Caution or Specialist Oversight

• Women of reproductive age on inclisiran who use NAC for PCOS and ovulation support. If conception is a goal, inclisiran must be paused or stopped per contraception requirements. NAC may continue for ovulation support under reproductive endocrinology guidance.
• Women taking high-dose NAC (>1,800 mg/day) alongside inclisiran for Lp(a) reduction. The additive effect on Lp(a) is theoretical and unstudied. A clinician should monitor Lp(a) levels every six months.
• Women with renal impairment. Both inclisiran (which has modest renal PK effects) and high-dose NAC (which is renally excreted) should be used with attention to kidney function. The inclisiran FDA label notes no dose adjustment is needed for mild-to-moderate renal impairment, but data in severe renal impairment are limited.

Not Recommended

• Women who are pregnant or actively trying to conceive should not take inclisiran, regardless of NAC co-administration.
• Women who are breastfeeding should not take inclisiran.

Monitoring If You Take Both

No special monitoring protocol beyond standard inclisiran follow-up is required for women who take NAC alongside Leqvio. Standard inclisiran monitoring includes:

• Fasting lipid panel at approximately 3 months after the first injection, then at each subsequent 6-month visit.
• Liver function is not routinely required (inclisiran does not carry a hepatotoxicity signal similar to statins), but a baseline is reasonable.
• If a woman is taking NAC at high doses for Lp(a) reduction, a baseline Lp(a) and repeat measurement at 6 months will clarify whether any additive benefit exists.
• Injection-site reactions are the most common side effect of inclisiran, reported in approximately 8.2 percent of patients in ORION-10, and are unrelated to NAC use.

The Evidence Gap: What We Do Not Know

Women have been underrepresented in lipid-lowering cardiovascular trials for decades. The ORION trials enrolled a meaningful proportion of women (approximately 30 to 40 percent), which is better than older statin trials, but PCOS-related dyslipidemia, perimenopausal lipid shifts, and postpartum lipid changes were not addressed as distinct subgroups. The combination of NAC and inclisiran has never been studied in any trial. The statements made here rest on the absence of a mechanistic basis for interaction, not on direct clinical data proving safety as a combination in women.

As WomanRx medical reviewer Dr. Maya Okafor notes: "The lack of a pharmacokinetic interaction between NAC and inclisiran is reassuring, but women with PCOS or perimenopausal cardiovascular risk are not the population studied in the ORION trials. Clinicians should treat these women as an evidence-extrapolated group and monitor accordingly, rather than assuming the trial results map perfectly onto their metabolic profile."

Practical Steps If You Are Taking or Considering Both

1. Tell your prescribing clinician you take NAC, with the dose and frequency. This is part of a complete medication and supplement list.
2. Do not stop inclisiran because of concern about a NAC interaction. No interaction has been identified.
3. If you are taking NAC for PCOS and your cardiologist or internist has prescribed inclisiran, loop in your gynecologist or reproductive endocrinologist if pregnancy is a future goal.
4. If you are postmenopausal and taking both for cardiovascular benefit, ask for a fasting lipid panel with Lp(a) at your next six-month inclisiran visit to see where your numbers land.
5. Use NAC at doses supported by evidence for your specific indication: 1,200 to 1,800 mg/day for PCOS metabolic effects, 600 mg twice daily for mucolytic purposes, or 600 mg once daily for general antioxidant supplementation.